Drug Therapy

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

David S. Geldmacher, MD
Department of Neurology, University of Virginia Health System, Charlottesville

Address: David S. Geldmacher, MD, Department of Neurology, University of Virginia Health System, PO Box 800394, Charlottesville, VA 22908; e-mail [email protected]

The author has indicated that he has received grant or research support from the Eisai and Pfizer corporations, is a consultant for the Eisai, Pfizer, and Forest corporations, and is on the speakers’ bureaus of the Eisai, Pfizer, Forest, and Astra-Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

David S. Geldmacher, MD
Department of Neurology, University of Virginia Health System, Charlottesville

Address: David S. Geldmacher, MD, Department of Neurology, University of Virginia Health System, PO Box 800394, Charlottesville, VA 22908; e-mail [email protected]

The author has indicated that he has received grant or research support from the Eisai and Pfizer corporations, is a consultant for the Eisai, Pfizer, and Forest corporations, and is on the speakers’ bureaus of the Eisai, Pfizer, Forest, and Astra-Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

David S. Geldmacher, MD
Department of Neurology, University of Virginia Health System, Charlottesville

Address: David S. Geldmacher, MD, Department of Neurology, University of Virginia Health System, PO Box 800394, Charlottesville, VA 22908; e-mail [email protected]

The author has indicated that he has received grant or research support from the Eisai and Pfizer corporations, is a consultant for the Eisai, Pfizer, and Forest corporations, and is on the speakers’ bureaus of the Eisai, Pfizer, Forest, and Astra-Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

David Martins, MD
Clinical Research Center, Charles R. Drew University of Medicine and Science, Los Angeles, CA

Keith Norris, MD
Clinical Research Center, Charles R. Drew University of Medicine and Science, Los Angeles, CA

Address: Keith Norris, MD, Clinical Research Center, 11705 Deputy Yamamoto Place, Suite B, Lynwood, CA 90262; e-mail [email protected]

Drs. Martins and Norris are supported by NIH grants PLO-RR11145, PZOMD000182, and U54RR019234.

David Martins, MD
Clinical Research Center, Charles R. Drew University of Medicine and Science, Los Angeles, CA

Keith Norris, MD
Clinical Research Center, Charles R. Drew University of Medicine and Science, Los Angeles, CA

Address: Keith Norris, MD, Clinical Research Center, 11705 Deputy Yamamoto Place, Suite B, Lynwood, CA 90262; e-mail [email protected]

Drs. Martins and Norris are supported by NIH grants PLO-RR11145, PZOMD000182, and U54RR019234.

David Martins, MD
Clinical Research Center, Charles R. Drew University of Medicine and Science, Los Angeles, CA

Keith Norris, MD
Clinical Research Center, Charles R. Drew University of Medicine and Science, Los Angeles, CA

Address: Keith Norris, MD, Clinical Research Center, 11705 Deputy Yamamoto Place, Suite B, Lynwood, CA 90262; e-mail [email protected]

Drs. Martins and Norris are supported by NIH grants PLO-RR11145, PZOMD000182, and U54RR019234.

Eduardo B. Saad, MD
The Center for Atrial Fibrillation, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Robert A. Schweikert, MD
The Center for Atrial Fibrillation, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Robert A. Schweikert, MD, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Eduardo B. Saad, MD
The Center for Atrial Fibrillation, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Robert A. Schweikert, MD
The Center for Atrial Fibrillation, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Robert A. Schweikert, MD, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Eduardo B. Saad, MD
The Center for Atrial Fibrillation, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Robert A. Schweikert, MD
The Center for Atrial Fibrillation, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Robert A. Schweikert, MD, Section of Electrophysiology and Pacing, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Susan M. Fosnight, RPh, CGP, BCPS
Clinical Staff Pharmacist, Department of Pharmacy, Summa Health System, Akron, OH

Kyle R. Allen, DO
Chief, Division of Geriatric Medicine, Medical Director, Post Acute and Senior Services, Summa Health System; Associate Professor of Clinical Internal and Family Medicine, Northeastern Ohio Universities College of Medicine, Akron, OH

Carolyn M. Holder, MSN, RN, CNS
Geriatrics Coordinator, Post Acute and Senior Services, Summa Health System, Akron, OH

Susan Hazelett, MSN, RN
Research Associate, Summa Health System, Akron, OH

Address: Susan M. Fosnight, RPh, CGP, BCPS, Department of Pharmacy, Summa Health System, 525 East Market Street, Akron, OH 44304; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Susan M. Fosnight, RPh, CGP, BCPS
Clinical Staff Pharmacist, Department of Pharmacy, Summa Health System, Akron, OH

Kyle R. Allen, DO
Chief, Division of Geriatric Medicine, Medical Director, Post Acute and Senior Services, Summa Health System; Associate Professor of Clinical Internal and Family Medicine, Northeastern Ohio Universities College of Medicine, Akron, OH

Carolyn M. Holder, MSN, RN, CNS
Geriatrics Coordinator, Post Acute and Senior Services, Summa Health System, Akron, OH

Susan Hazelett, MSN, RN
Research Associate, Summa Health System, Akron, OH

Address: Susan M. Fosnight, RPh, CGP, BCPS, Department of Pharmacy, Summa Health System, 525 East Market Street, Akron, OH 44304; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Susan M. Fosnight, RPh, CGP, BCPS
Clinical Staff Pharmacist, Department of Pharmacy, Summa Health System, Akron, OH

Kyle R. Allen, DO
Chief, Division of Geriatric Medicine, Medical Director, Post Acute and Senior Services, Summa Health System; Associate Professor of Clinical Internal and Family Medicine, Northeastern Ohio Universities College of Medicine, Akron, OH

Carolyn M. Holder, MSN, RN, CNS
Geriatrics Coordinator, Post Acute and Senior Services, Summa Health System, Akron, OH

Susan Hazelett, MSN, RN
Research Associate, Summa Health System, Akron, OH

Address: Susan M. Fosnight, RPh, CGP, BCPS, Department of Pharmacy, Summa Health System, 525 East Market Street, Akron, OH 44304; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.